81 completed, 7 terminated, 6 active not recruiting, 5 recruiting. 105 Phase 1, 17 Phase 2.
Follow Pneumovirus Infections: new trials by email Literature Review of Pneumovirus Infections trials Research Report on Pneumovirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults Bivalent RSV Vaccine (IN006), Placebo - Respiratory Syncytial Virus Infections | Phase 1 | Not yet recruiting | Shenzhen Shenxin Biotechnology Co., Ltd | 200 | 2026-12-01 | 2026-04-13 |
| Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant) - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Recruiting | Ab&B Bio-tech Co., Ltd.JS | 470 | 2026-05-14 | 2026-05-27 |
| Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3 - Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | Phase 1 | Recruiting | Sanofi | 570 | 2026-04-15 | 2026-05-08 |
| Safety and Immunogenicity Study of SCB-1019T in Children low dose SCB-1019T, adjuvanted low dose SCB-1019T, high dose SCB-1019T - RSV Infection | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2025-10-01 | 2024-12-31 | |
| Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age RSV vaccine formulation 1 dose, RSV vaccine formulation 2 dose, RSV vaccine formulation 3 dose - Respiratory Syncytial Virus Immunization | Phase 1 | Completed | Sanofi | 240 | 2025-07-14 | 2026-04-28 |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults SCB-1019T, SCB-1022, SCB-1033 - RSV Infection, Human Metapneumovirus Infection | Phase 1 / Phase 2 | Active not recruiting | Clover Biopharmaceuticals AUS Pty | 612 | 2025-06-18 | 2026-10-26 |
| Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older Low dose antigen of LYB005 without A01B adjuvant, Low dose antigen of LYB005 with A01B adjuvant, Middle dose antigen of LYB005 without A01B adjuvant - Respiratory Syncytial Virus Infection | Phase 1 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 90 | 2025-04-15 | 2025-08-22 |
| Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults Candidate vaccine, SCB-1019T, AREXVY, placebo - RSV Infection | Phase 1 | Recruiting | Clover Biopharmaceuticals USA, LLC | 160 | 2025-03-21 | 2025-05-14 |
| A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants EDP-323, Midazolam, Caffeine - RSV Infection, Drug Drug Interaction | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 24 | 2025-03-13 | 2025-07-01 |
| A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. EDP-323, Itraconazole, carbamazepine - RSV Infection, Drug Drug Interaction (DDI) | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 48 | 2025-01-27 | 2025-07-01 |
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above Bivalent RSV Vaccine (IN006), Placebo - Respiratory Syncytial Virus Infections | Phase 1 | Active not recruiting | Shenzhen Shenxin Biotechnology Co., Ltd | 240 | 2024-11-11 | 2026-04-02 |
| Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent) - Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization | Phase 1 / Phase 2 | Active not recruiting | Sanofi Pasteur, a Sanofi Company | 1530 | 2024-11-11 | 2025-12-11 |
| Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years RSV/hMPV vaccine dose A1, RSV/hMPV vaccine dose A2, RSV/hMPV vaccine dose A3 - RSV Infection, hMPV | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 385 | 2024-10-09 | 2025-11-20 |
| Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) Placebo comparator, PRS CK STORM - SARS-CoV-2, Influenza, Human | Phase 1 / Phase 2 | Recruiting | PEACHES BIOTECH | 50 | 2024-10-02 | 2026-06-10 |
| A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3 - Respiratory Syncytial Virus Infections | Phase 1 | Completed | GlaxoSmithKline | 213 | 2024-09-30 | 2026-07-30 |
| Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older parainfluenza virus type 3 vaccine (PIV3), RSV/hMPV/PIV3 vaccine, RSV/hMPV vaccine - Respiratory Syncytial Virus Infection, Metapneumovirus Infection | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 390 | 2024-09-17 | 2026-04-23 |
| A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults LYB005 low dose without adjuvant, LYB005 middle dose without adjuvant, LYB005 high dose without adjuvant - Respiratory Syncytial Virus (RSV), RSV Infection | Phase 1 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 84 | 2024-07-31 | 2025-03-13 |
| A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo - RSV Infection, QTc Interval | Phase 1 | Completed | Enanta Pharmaceuticals, Inc | 72 | 2024-07-15 | 2025-07-28 |
| Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years EuRSV, Placebo Comparator - Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV) | Phase 1 | Active not recruiting | EuBiologics Co.,Ltd | 100 | 2024-05-08 | 2025-06-15 |
| A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults STR-V003/Placebo - Respiratory Syncytial Virus Infections | Phase 1 / Phase 2 | Unknown | Starna Therapeutics | 48 | 2024-05-01 | 2024-04-03 |
Showing 20 of 105. Sign in to see all of them.
Respiratory Syncytial Virus Infections (105) · Respiratory Tract Infections (5) · Virus Diseases (5) · Influenza, Human (2) · Paramyxoviridae Infections (2) · Bronchiolitis (1) · COVID-19 (1) · Cytokine Release Syndrome (1) · Lung Diseases (1) · Pneumonia (1) · Respiratory Distress Syndrome (1) · Systemic Inflammatory Response Syndrome (1)
Infections (105) · Mononegavirales Infections (105) · RNA Virus Infections (105) · Paramyxoviridae Infections (103) · Virus Diseases (100) · Respiratory Tract Diseases (8) · Respiratory Tract Infections (3) · Orthomyxoviridae Infections (2) · Bronchial Diseases (1) · Bronchitis (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Inflammation (1) · Lung Diseases (1)
EDP-938 (6) · Saline Solution (6) · 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (4) · Midazolam (4) · gontivimab (4) · sisunatovir (4) · Itraconazole (3) · VP-14637 (3) · Adjuvants, Pharmaceutic (2) · Fluconazole (2) · Quinidine (2) · Rifampin (2) · Rosuvastatin Calcium (2) · Vaccines (2) · XW001 (2)
National Institute of Allergy and Infectious Diseases (NIAID) (18) · Enanta Pharmaceuticals, Inc (9) · GlaxoSmithKline (8) · Sanofi Pasteur, a Sanofi Company (7) · Pfizer (6) · MedImmune LLC (5) · Ablynx, a Sanofi company (4) · Alios Biopharma Inc. (3) · MicroDose Therapeutx, Inc (3) · Bavarian Nordic (2) · Blue Lake Biotechnology Inc. (2) · Clover Biopharmaceuticals AUS Pty (2) · Codagenix, Inc (2) · Gilead Sciences (2) · Guangzhou Patronus Biotech Co., Ltd. (2)
United States (58) · Australia (18) · United Kingdom (11) · China (9) · Spain (6) · Japan (5) · Belgium (4) · Canada (4) · Chile (4) · Germany (3) · Panama (3) · Poland (3) · South Africa (3) · Thailand (3) · Argentina (2)
Ruth A. Karron, MD (9) · Coleen Cunningham, MD (2) · Genevieve Losonsky, MD (2) · Matthew McClure, M.D. (2) · Oliver Medzihradsky, MD MPH MS (2) · Qin Yu (2) · Steven De Bruyn, MD (2) · Alexis M Kalergis, PhD (1) · Andrew J Pollard, FRCPCH PhD (1) · Anthony Gilbert, MD (1)
PMID 29509911, PMID 29509929, PMID 31211158, PMID 21926667, PMID 23153449, PMID 26268313, PMID 26510727, PMID 27956428, PMID 28000669, PMID 31951765, PMID 32006006, PMID 32201897, PMID 33073219, PMID 33216113, PMID 35454123, PMID 35732186, PMID 35904987, PMID 36484484, PMID 36641341, PMID 37467213, PMID 37477875, PMID 37493269, PMID 37533867, PMID 37878713, PMID 39052716, PMID 39627701, PMID 39696004, PMID 40856556, PMID 41673909, PMID 42549136, PMID 42869044
2018 (4), 2023 (2), 2014 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1)